Literature DB >> 29614520

Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.

Alexander Kaserer1, Andreas Schedler1, Alexander Jetter2, Burkhardt Seifert3, Donat R Spahn1, Philipp Stein1, Jan-Dirk Studt4.   

Abstract

INTRODUCTION: Rivaroxaban (RXA) is a direct oral factor Xa (Xa) antagonist with a short half-life and a fast onset and offset of effect. Before elective surgery, discontinuation is recommended with an interval of at least > 24 hours. In clinical practice, this is, however, not always sufficient to achieve a residual RXA plasma concentration deemed appropriate for surgery, defined as ≤ 50 mcg/L. Our study aimed at identifying factors associated with a higher-than-expected residual RXA plasma concentration in a large group of real-life patients.
MATERIALS AND METHODS: This retrospective single-centre study included all patients taking RXA between 2012 and 2016 where RXA plasma concentration was determined by pharmacodynamic anti-Xa assay (518 measurements in 368 patients). Medical records were reviewed. Residual RXA plasma concentrations were then compared with expected values according to a pharmacokinetic model.
RESULTS: Residual RXA plasma concentration was significantly higher-than-expected in patients with atrial fibrillation, impaired kidney function (glomerular filtration rate [GFR] < 60 mL/min), CYP3A4-, CYP2J2- and PGP-inhibitory co-medication including amiodarone. Impaired kidney function (odds ratio [OR], 2.22, 95% confidence interval [CI], 1.30-3.78, p = 0.003) and concomitant amiodarone intake (OR, 1.97, 95% CI, 1.04-3.72, p = 0.036) were significantly associated with RXA plasma concentrations > 50 mcg/L at 24 to 48 hours after the last RXA intake.
CONCLUSION: In our group of real-life patients, impaired kidney function (GFR < 60 mL/min) and co-medication with amiodarone were independently associated with higher-than-expected residual RXA plasma concentrations. In these patients, standard intervals of RXA discontinuation may not always be sufficient before elective surgery and routine pre-operative determination of the residual RXA concentration could be advisable. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29614520     DOI: 10.1055/s-0038-1639585

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  NOACs in Anesthesiology.

Authors:  Donat R Spahn; Jürg-Hans Beer; Alain Borgeat; Pierre-Guy Chassot; Christian Kern; François Mach; Krassen Nedeltchev; Wolfgang Korte
Journal:  Transfus Med Hemother       Date:  2019-01-29       Impact factor: 3.747

3.  Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.

Authors:  Tamana Meihandoest; Jan-Dirk Studt; Adriana Mendez; Lorenzo Alberio; Pierre Fontana; Walter A Wuillemin; Adrian Schmidt; Lukas Graf; Bernhard Gerber; Ursula Amstutz; Cedric Bovet; Thomas C Sauter; Lars M Asmis; Michael Nagler
Journal:  Front Cardiovasc Med       Date:  2022-03-17

4.  Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study.

Authors:  Vepusha Sathanantham; Lorenzo Alberio; Cédric Bovet; Pierre Fontana; Bernhard Gerber; Lukas Graf; Adriana Mendez; Thomas C Sauter; Adrian Schmidt; Jan-Dirk Studt; Walter A Wuillemin; Michael Nagler
Journal:  Life (Basel)       Date:  2022-07-11

5.  Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

Authors:  Anne-Laure Sennesael; Anne-Sophie Larock; Jonathan Douxfils; Laure Elens; Gabriel Stillemans; Martin Wiesen; Max Taubert; Jean-Michel Dogné; Anne Spinewine; François Mullier
Journal:  Thromb J       Date:  2018-11-12

6.  Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations.

Authors:  Alexander Kaserer; Andreas Schedler; Burkhardt Seifert; Donat R Spahn; Jan-Dirk Studt; Philipp Stein
Journal:  Perioper Med (Lond)       Date:  2019-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.